The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a more substantial decrease in body mass and improve metabolic health, particularl